Clinical Trial Update: Postmenopausal Estrogen/Progestin Interventions (PEPI) [Phase 3]

View source ↗

Summary

Phase 3 PEPI trial completed. The study evaluated postmenopausal estrogen/progestin interventions for effects on bone health and cardiovascular risk.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cardiovascular Disease
• Coronary Artery Disease
• Diabetes Mellitus
• Hypercholesterolemia
• Hypertension
• Myocardial Ischemia
• Osteoporosis
• Thrombosis

Drugs mentioned

• Conjugated Estrogens (ESTROGENS, CONJUGATED)
• Conjugated estrogens/medroxyprogesterone acetate (conjugated estrogens/medroxyprogesterone acetate)
• Medroxyprogesterone acetate (Medroxyprogesterone acetate)

Snippet

Sponsor: National Heart, Lung, and Blood Institute (NHLBI) | Conditions: Bone Diseases, Cardiovascular Diseases | Phase 3 | Status: COMPLETED